BridgeBio Pharma is a brand committed to developing meaningful treatment options for individuals with achondroplasia. They prioritize understanding the needs of the community, including patients, their families, and healthcare professionals. Through diligent research, BridgeBio Pharma aims to address those needs and provide valuable insights for care decisions and supporting individuals in living well with achondroplasia.

They embrace the voices of the achondroplasia community, sharing unique stories and advocating for their needs. BridgeBio Pharma is currently engaged in clinical studies and research on FGFR3 signaling to explore new possibilities for treatment. As an affiliate company of QED Therapeutics, they are dedicated to bringing positive change for those affected by achondroplasia.

Stay informed and connected with BridgeBio Pharma to access valuable resources and stay up to date with the latest developments in the field